Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04187196 · ClinicalTrials.gov registry record · Phase 4
Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
NCT04187196 is a Phase 4 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 73 participants.
The verdict
NCT04187196, a Phase 4 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
Study Summary
A randomized, open-blinded, prospective study to evaluate the timeliness and safety of direct current cardioversion (DCCV) when using methohexital when compared to the more often used propofol.
Interventions
- DRUG Propofol
- DRUG Methohexital
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2020-04-29 |
| Est. Completion | 2022-09-28 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04187196
The ClinicalTrials.gov registry entry for NCT04187196 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propofol is the first listed.
NCT04187196 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04187196 about?
NCT04187196 is a clinical study titled "Comparison of Bolus Dosing of Methohexital and Propofol in Elective Direct Current Cardioversion". A randomized, open-blinded, prospective study to evaluate the timeliness and safety of direct current cardioversion (DCCV) when using methohexital when compared to the more often used propofol.
What is the current status of trial NCT04187196?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2020-04-29. Estimated completion is 2022-09-28.
What interventions are being tested in trial NCT04187196?
The interventions under investigation include: Propofol (DRUG), Methohexital (DRUG).
Who is sponsoring clinical trial NCT04187196?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.